{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-018837","form_type":"8-K","ticker":"IOVA","cik":"0001425205","company_name":"IOVANCE BIOTHERAPEUTICS, INC.","filed_at":"2026-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.052078+00:00","generated_at":"2026-05-16T00:46:32.312915+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Iovance Q4 product revenue $87M (30% QoQ), FY2025 $264M; FDA Fast Track for NSCLC","bullets":["Q4 product revenue ~$87M, up ~30% QoQ; FY2025 total $264M, within $250-300M guidance.","Gross margin improved to ~50% in Q4; cash $303M funds operations into Q3 2027.","FDA Fast Track granted for lifileucel in second-line advanced nonsquamous NSCLC; potential launch 2H27.","Real-world Amtagvi ORR ~44% at Tandem Meetings; 52% in patients with ≤2 prior lines.","Sarcoma early data: 50% ORR (6 evaluable); registrational trial to start Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-018837","json":"https://secwatch.observer/filing/0001104659-26-018837.json","markdown":"https://secwatch.observer/filing/0001104659-26-018837.md","text":"https://secwatch.observer/filing/0001104659-26-018837.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/0001104659-26-018837-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1425205/000110465926018837/tm266992d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T00:46:32.312915+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}